Literature DB >> 20429626

Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results.

Z Molnar1, Z Simon, Z Borbenyi, B Deak, L Galuska, K Keresztes, Z Miltenyi, I Marton, A Rosta, T Schneider, L Tron, E Varady, A Illes.   

Abstract

Determining the viability of residual tumor masses is a great challenge after primary treatment of Hodgkin lymphoma. FDG-PET may play a crucial role in this procedure. In this study, files of 128 Hodgkin lymphoma patients were reviewed, who were treated in three Hungarian hematology centers between January 1995 and February 2005. CT scan showed residual tumor mass by all of them. Their median follow-up was 75.5 months from PET examination. The number of true-positive, true-negative, false-positive, false-negative subjects were 29, 83, 10, 6, respectively. Sensitivity of post-treatment FDG-PET was 83 %, specificity 93 %, positive predictive value 74 %, negative predictive value 93 %, and accuracy 88 %. The difference between the event free survival of PET positive and negative cases is highly significant (p=0.0000), according to the Mantel-Cox test. Our results in the largest cohort of patients, in accordance with literature, clearly indicates that patients with negative FDG-PET results are unlikely to progress or relapse during the longest follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20429626

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  4 in total

1.  Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.

Authors:  Laura Galvez-Carvajal; Cristina Quero; María Casanova; Carola Díaz; Jose Reinaldo Chícharo; Manuel Espeso; Ángeles Medina; Inmaculada Ramos; Emilio Alba; Antonio Rueda
Journal:  Int J Hematol       Date:  2021-09-21       Impact factor: 2.490

2.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2019-09-16

3.  Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.

Authors:  Yvette L Kasamon
Journal:  Adv Hematol       Date:  2010-12-22

4.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.